Cardiovasc Diabetol: 3-year prognosis of patients with diabetes (pre-stage) after percutaneous coronary intervention with drug-eluting stents

Diabetes is associated with poor outcomes after percutaneous coronary intervention with drug-eluting stents (DES), but it is unclear whether this association also exists in pre-diabetes

diabetes

This is a post-mortem analysis study that pooled patient-level data from the BIO-RESORT and BIONYX stent trials.

Vascular Cardiovascular Myocardial Infarction

Target vessel treatment failure and cardiovascular mortality in three groups of subjects

Target vessel treatment failure and cardiovascular mortality in three groups of subjects

The baseline cardiovascular risk status of patients with normal blood sugar, prediabetes and diabetes is gradually abnormal

The incidence of the primary endpoints for normal blood sugar, prediabetes, and diabetic patients were 6.

Target vessel myocardial infarction or target vessel reconstruction rate of the three groups of subjects

Target vessel myocardial infarction or target vessel reconstruction rate of the three groups of subjects

Compared with individuals with normal blood sugar, the cardiovascular mortality and target vessel remodeling rate in prediabetes patients were significantly higher (HR 2.

Compared with individuals with normal blood sugar, the cardiovascular mortality and target blood vessel remodeling rate of patients with prediabetes are significantly higher.

Major bleeding rate of three groups of subjects

Major bleeding rate of three groups of subjects

Compared with individuals with normal blood sugar, the rate of major bleeding in prediabetes and diabetic patients was also significantly higher (3.

In summary, not only patients with diabetes , but also patients with pre-diabetes have a significantly higher risk of adverse outcomes after percutaneous coronary intervention with drug-eluting stents

Not only patients with diabetes, the risk of adverse outcomes after percutaneous coronary intervention in patients with prediabetes is also significantly increased after drug-eluting stents is not only in diabetic patients, but also after percutaneous coronary intervention in patients with prediabetes after drug-eluting stents The risk of adverse outcomes is also significantly higher

Original source:

Original source:

Ploumen, EH, Pinxterhuis, TH, Zocca, P.

Impact of prediabetes and diabetes on 3- year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trial

in this message